Ann Oncol

1. HONG SD, Wang YS, Zhao HY, Zhao YY, et al
   Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.
   Ann Oncol. 2026;37:813-824.
   

   >> Share

   
   
2. RIESS JW, Yu HA, Le X, de Langen AJ, et al
   Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
   Ann Oncol. 2026;37:825-836.
   

   >> Share

   
   

   
   Ann Surg Oncol

3. KHAN MS, Leonard T, Williams N, Mallick S, et al
   Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and Pancreatic Cancer Survival.
   Ann Surg Oncol. 2026 May 17. doi: 10.1245/s10434-026-19760.
   

   >> Share

   
   
4. CUMMINS KC, Sears O, Bitar ER, Shen C, et al
   Hormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma.
   Ann Surg Oncol. 2026;33:5304-5314.
   

   >> Share

   
   

   
   BMC Cancer

5. REN N, Ma F, Tian M, Qu X, et al
   The impact of facilitating patient involvement on decisional conflict among patients undergoing surgical treatment for lung cancer: the serial mediating roles of hope level and social support.
   BMC Cancer. 2026 May 21. doi: 10.1186/s12885-026-16195.
   

   >> Share

   
   
6. HANNA NM, Shakeel S, Akhtar-Danesh GG, Finley C, et al
   A population-based study on the impact of social determinants of health on time to treatment of stage I lung cancer in Ontario, Canada.
   BMC Cancer. 2026 May 20. doi: 10.1186/s12885-026-15875.
   

   >> Share

   
   
7. SHAN J, Yu J, Zhao L, Yang D, et al
   Impact of chemotherapy dose reduction during concurrent chemoradiotherapy on survival outcomes in limited-stage small-cell lung cancer.
   BMC Cancer. 2026 May 21. doi: 10.1186/s12885-026-16150.
   

   >> Share

   
   
8. HU L, Zhu X, Chen X, Yang F, et al
   Histological transformation in lung cancer: a single-arm meta-analysis and systematic review.
   BMC Cancer. 2026 May 21. doi: 10.1186/s12885-026-16114.
   

   >> Share

   
   

   
   Br J Cancer

9. SKRIBEK M, Livanou ME, Vathiotis I, Strandman V, et al
   The brain-lung immunotherapy prognostic (BLIP) Score: a novel robust tool for prognostication in non-small cell lung cancer patients with brain metastases.
   Br J Cancer. 2026 May 20. doi: 10.1038/s41416-026-03470.
   

   >> Share

   
   
10. CHEN Y, Chen Q, Li Q, Guo J, et al
    A novel microprotein L3EMP triggers lung adenocarcinoma progression by catalysing the deubiquitination of SIRT1.
    Br J Cancer. 2026;134:1541-1556.
    

    >> Share

    
    
11. WANG X, Xie Y, Hu J, Liu N, et al
    Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes.
    Br J Cancer. 2026;134:1614-1623.
    

    >> Share

    
    
12. LOPEZ JS, Harrington KJ, Im SA, Lee KW, et al
    Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
    Br J Cancer. 2026;134:1568-1579.
    

    >> Share

    
    

    
    Cancer Cell

13. DIJKSTRA KK, Vendramin R, Karagianni D, Witsen M, et al
    Subclonal immune evasion in non-small cell lung cancer.
    Cancer Cell. 2026 May 18:S1535-6108(26)00224-2. doi: 10.1016/j.ccell.2026.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

14. BLECHTER B, Shu XO, Hu W, Francis ER, et al
    Mitochondrial DNA breaks and copy number and the risk of lung cancer in the Shanghai Women's Health Study.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    
15. NAGHASH M, Shaner RL, Poustchi H, Roshandel G, et al
    ?Biomarkers of opioids, volatile organic compounds, and polycyclic aromatic hydrocarbons and lung cancer incidence among opium users.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Chest

16. YAMADA Y, Fujiwara M, Ishii T, Watanabe T, et al
    Impact of pre-existing schizophrenia spectrum disorder on the receipt of surgery and other treatments for non-small cell lung cancer: A multicenter nationwide cohort study in Japan.
    Chest. 2026 May 20:S0012-3692(26)00649-5. doi: 10.1016/j.chest.2026.
    

    >> Share

    
    
17. KIM YW, Oh J, Park J, Kim M, et al
    Performance and Utility of the Sybil Deep Learning Model for Lung Cancer Risk Prediction in Asian High- and Low-Risk Populations.
    Chest. 2026 May 14:S0012-3692(26)00631-8. doi: 10.1016/j.chest.2026.
    

    >> Share

    
    

    
    Clin Cancer Res

18. NINOMIYA T, Fang C, Hamano H, Morinaga T, et al
    Incidence of B cell malignancies in patients with lung cancer receiving PD-1 blockade therapy.
    Clin Cancer Res. 2026 May 18. doi: 10.1158/1078-0432.CCR-25-3406.
    

    >> Share

    
    

    
    Eur J Cancer

19. SIKKEMA BJ, Veerman M, Hoop EO, Paats MS, et al
    Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.
    Eur J Cancer. 2026;240:116742.
    

    >> Share

    
    
20. JIANG B, Lancaster HL, Davies MPA, Han D, et al
    Incidence and lung cancer probability of new nodules in the UK lung screening trial.
    Eur J Cancer. 2026;241:116779.
    

    >> Share

    
    

    
    Eur Respir J

21. KOREVAAR DA, Kovacevic B, Papadopoulou E, van den Broek FJC, et al
    ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
    Eur Respir J. 2026 May 21:2600097. doi: 10.1183/13993003.00097-2026.
    

    >> Share

    
    
22. CLEMENTS D, Babaei-Jadidi R, Johnson J, Miller S, et al
    Extracellular matrix deposition drives disease progression and reduces rapamycin response in lymphangioleiomyomatosis.
    Eur Respir J. 2026;67:2500492.
    

    >> Share

    
    

    
    Int J Cancer

23. YU C, Wan J, Jin C, Li C, et al
    Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases.
    Int J Cancer. 2026 Feb 25. doi: 10.1002/ijc.70405.
    

    >> Share

    
    
24. MI X, Zhang X, Lai H, Zheng Q, et al
    Real-World Outcomes of Induction Immunochemotherapy Followed by Surgery for Advanced Non-Small Cell Lung Cancer.
    Int J Cancer. 2026 May 20. doi: 10.1002/ijc.70499.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

25. JIANG Y, Yang Y, Wu L, Wang J, et al
    Peripheral PD-1(+)CD8(+) T-cell TCR Dynamics During Radiation Therapy Predict Survival in Unresectable Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026 May 16:S0360-3016(26)00574.
    

    >> Share

    
    
26. YANG J, Zhu T, Zhou J, Ni C, et al
    A Meta-Analysis-Based Risk Score for Predicting Radiation Pneumonitis After Thoracic Radiotherapy for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026 May 14:S0360-3016(26)00719.
    

    >> Share

    
    
27. RODRIGUEZ-RUSSO C, Chang L
    A PORT Yet Uncharted: The Evidence Gap for Postoperative Radiation Therapy Following Neoadjuvant Chemoimmunotherapy in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026;125:370.
    

    >> Share

    
    
28. ZHAO J, Vaios E, Calabrese E, Yang Z, et al
    An Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery.
    Int J Radiat Oncol Biol Phys. 2025 Nov 27:S0360-3016(25)06522.
    

    >> Share

    
    
29. LADBURY C, Chun SG
    When the Nodes Don't Get the Memo: New Era, Same Conclusion on Postoperative Radiation Therapy for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026;125:368.
    

    >> Share

    
    

    
    J Clin Invest

30. ISOMOTO K, Haratani K, Tsujikawa T, Tomida S, et al
    Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC.
    J Clin Invest. 2026;136:e195021.
    

    >> Share

    
    
31. ZOU T, Minna JD
    Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment.
    J Clin Invest. 2026;136:e206316.
    

    >> Share

    
    

    
    J Clin Oncol

32. DUKE ES, Bradford D, Sinha AK, Li X, et al
    Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.
    J Clin Oncol. 2026;44:1457-1464.
    

    >> Share

    
    

    
    Lung Cancer

33. LEEVAN E, Pinsky P
    Subsequent risk of lung cancer in patients with positive low-dose CT screens and initial negative lung biopsy.
    Lung Cancer. 2026;217:109457.
    

    >> Share

    
    
34. MICHAELS-IGBOKWE C, Collacott H, Krucien N, Sandelin M, et al
    Patient and clinician preferences for adjuvant treatment following surgical resection in early-stage non-small cell lung cancer: A multi-country discrete choice experiment.
    Lung Cancer. 2026;217:109460.
    

    >> Share

    
    
35. CULVER KW, Farmen S, Seo J, Whitty JA, et al
    Patient and caregiver priorities of treatment characteristics influencing preferences for tyrosine kinase inhibitors in anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.
    Lung Cancer. 2026;217:109449.
    

    >> Share

    
    
36. AGUILAR A, Cobo M, Calles A, Azkarate A, et al
    Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.
    Lung Cancer. 2026;217:109461.
    

    >> Share

    
    
37. DAWES K, Mills JA, Hoffman RM, Froehlich EM, et al
    A DNA Methylation-based algorithm Improves Lung Cancer risk prediction in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Lung Cancer. 2026;217:109462.
    

    >> Share

    
    
38. SCHLIEMANN A, Waldmann A, Katalinic A, Kim-Wanner SZ, et al
    Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study.
    Lung Cancer. 2026;217:109448.
    

    >> Share

    
    

    
    Mol Carcinog

39. HU X, Yang X, Jin P, Tian J, et al
    A Combinatorial Model of Serum tsRNAs as a Diagnostic Biomarker for Non-Small Cell Lung Cancer.
    Mol Carcinog. 2026 May 15. doi: 10.1002/mc.70124.
    

    >> Share

    
    

    
    PLoS One

40. TANG G, Li X, Liu H, Song S, et al
    Double-cuff versus single-cuff bronchial blockers for video-assisted thoracoscopic lobectomy: A randomized controlled trial.
    PLoS One. 2026;21:e0350007.
    

    >> Share

    
    
41. BIAN G, Zhang Y, Shen Y, Xiao P, et al
    In-silico prediction of multi?target mechanisms of Pinellia ternata phytochemicals in lung cancer: Evidence from a graph?attention?guided virtual screening and multi?scale simulations.
    PLoS One. 2026;21:e0349376.
    

    >> Share

    
    
42. AN D, Shi Z, Zhang C, Song S, et al
    Disease burden of asbestos-related diseases in China (1990-2023) based on GBD estimates: A call for stronger labor protection laws.
    PLoS One. 2026;21:e0349392.
    

    >> Share

    
    
43. VARGAS DY, Kramer FR
    SuperSelective PCR primers for determining cis/trans configurations of mutations within the same gene.
    PLoS One. 2026;21:e0349389.
    

    >> Share

    
    
44. CINTI L, Tuosto L, Roberto P, Campagna R, et al
    Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors.
    PLoS One. 2026;21:e0349500.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

45. FREITAG KM, Scheuplein R, Orlacchio C, Ansuinelli V, et al
    Light-controlled disruption of cancer cell dormancy via photoswitchable stress hormone receptor degraders.
    Proc Natl Acad Sci U S A. 2026;123:e2528760123.
    

    >> Share

    
    

    
    Semin Oncol

46. ALTUHAIFA FA, Pereira AP, Tuhaifa MAA, Alshaikhahmed H, et al
    Evaluating the ability of generative AI to standardize TNM staging data in lung cancer.
    Semin Oncol. 2026;53:152485.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share